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Abstract
Background: Parent carers of disabled children are at increased risk of mental and physical health problems. They
often experience challenges to maintaining good health which have implications for their well-being and their
ability to care for their children. In response to these needs, researchers and parent carers developed the Healthy
Parent Carers (HPC) programme. It is a peer-led, group-based intervention that promotes behaviours associated
with health and well-being. The aims of this trial are to assess the acceptability of the HPC programme and the
feasibility of its delivery in the community and to assess the feasibility and acceptability of the design of the
definitive trial to evaluate the programme’s effectiveness and cost-effectiveness.
Methods: We will establish six research sites and train facilitators to deliver the manualised intervention. Parent
carers of children with special educational needs and disabilities will be individually randomised, stratified by group
delivery site, to either take part in a group programme and online resources (intervention) or to receive access to
the online resources only (control). Measures of mental health; well-being; health-related quality of life; health
behaviours; patient activation; protective factors such as resilience, social connections, and practical support; and
use of health care, social care, and wider societal resources will be collected before randomisation (baseline),
immediately post-intervention, and 6 months later. Recruitment of participants, adherence to the programme, and
the dose received will be assessed. Group sessions will be audio-recorded to evaluate the fidelity of delivery and
participant engagement. Participants’ and facilitators’ feedback on the programme content and delivery, their
experience, and the acceptability of the outcome measures and trial design will be collected through feedback
forms, interviews, and focus groups.
Discussion: This trial will assess whether the programme delivery and evaluative trial design are feasible, to inform
whether to progress to a definitive randomised controlled trial to test the effectiveness and cost-effectiveness of
the Healthy Parent Carers programme.
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Background
There are an estimated 960,000 disabled children in the
UK, which is 7.3% of the population of children aged
0–18 years [1]. Parent carers of disabled children
commonly report higher levels of stress and depression
[2–11] and poorer physical health [3, 4, 7, 8, 12–14] than
parents of typically developing children. Population-based
studies suggest these health problems persist and may
worsen over time [15]. These problems have implications
for their ability to care for their children.
Parent carers often find the demands of caregiving
have a negative impact on their physical and emotional
health. Nevertheless, it is important to acknowledge that
not all parents of disabled children report that their
child’s difficulties negatively affect their psychological or
physical health [5], and in fact, some report positive im-
pacts [8, 16]. Indeed, some parent carers may perceive a
high burden with looking after a child with a relatively
‘mild’ condition whereas others, whose child may have
more severe disabilities, may not perceive caring as high
a burden [4].
Some interventions target external factors, such as
navigating healthcare services [17], while others target
levels of stress [18, 19] or emotional and social support
[20]. A systematic review of psychological therapies for
parents of children with chronic illness suggested prom-
ising results in terms of improved parent mental health,
particularly for problem-solving therapy [21]. No bene-
fits were found for cognitive behavioural therapy or fam-
ily therapy on parent outcomes; however, the quality of
the evidence was low and analyses were limited by lack
of data available to the reviewers. A systematic review of
mindfulness interventions for parents of children with
autism indicated potentially positive effects on parents’
stress levels and psychological well-being, with studies
reporting good attendance and retention in 8-week pro-
grammes [22]. There is growing evidence that groups
can facilitate change processes beneficial to health and
well-being [23, 24] by enabling the formation of strong
psychological connections and/or social identification
with other group members which can enhance engage-
ment, and thus possibly increase the interventions’ ef-
fectiveness [25, 26].
The idea for this research came directly from parent
carers who had been involved in a study evaluating peer
support for parent carers [20]. They wanted to extend
the benefits of emotional support to specific strategies to
improve health and well-being. Researchers and parent
carers in the Peninsula Childhood Disability Research
Unit (PenCRU) Family Faculty co-created the Healthy
Parent Carers (HPC) programme [27].
Previously, we tested the principle and acceptability of a
6-week intervention programme with one group of seven
parent carers, delivered by the intervention developers.
The intervention was developed using Intervention
Mapping [28] and extensive stakeholder engagement and
is described in detail in a separate paper [29]. Participants
had children with various conditions including autism,
cerebral palsy, and acquired brain injury. Retention of
participants in our preliminary study was high with all
staying until the end of the 6-week programme and 2-
month follow-up. Participants’ and facilitators’ feedback
were positive, indicating the intervention was feasible to
deliver and acceptable to, and valued by, participants. The
intervention content and delivery methods were refined
following feedback, and the manual was updated.
This feasibility trial will provide information that will
be used to determine whether to progress to a definitive
trial of the HPC programme, which would have the
following objectives:
1) To determine whether the peer-led, group-based
HPC programme is more effective at improving
health and well-being compared to providing online
information only
2) To estimate the costs of delivering the HPC
programme, and the cost-effectiveness of the
programme, versus the provision of online
information
3) To understand how the Healthy Parent Carers
intervention is working, for whom, and in what
context to inform the implementation of the
programme should it be shown to be effective
The current trial aims to assess the acceptability of the
HPC programme and the feasibility of its delivery in the
community, as well as the feasibility and acceptability of the
design of the definitive trial in order to evaluate whether a
fully powered randomised controlled trial is warranted and
to determine the optimal trial design.
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Methods
Objectives
This trial has two overarching aims:
1. To evaluate whether the programme can be
delivered in the community by facilitators other
than the developers, specifically to:
(a) Assess the feasibility of establishing venues, and
identifying and training group facilitators to be
in a position to deliver the intervention
(b) Assess the fidelity of intervention delivery in
terms of format, content, and quality
(c) Assess the experience and engagement of
participants, facilitators, and trainers
(d) Assess the programme attendance
2. To provide information necessary to design a
definitive randomised controlled trial, specifically to:
(a) Assess the feasibility of recruiting participants in
different sites
(b) Assess the acceptability of randomisation of
parent carers
(c) Assess the attrition and completion and
proportion of any missing data in questionnaire
measures
(d) Appraise the performance of candidate health
and well-being outcome measures in terms of
acceptability to participants, and feasibility and
interpretability for researchers
(e) Estimate the variability (standard deviation) and
the level of clustering within programme
delivery groups in the intervention arm to help
inform the sample size calculation for the
definitive trial
(f) Test the proposed cost-effectiveness framework
for a future randomised trial
This will help inform whether to progress to a defini-
tive randomised controlled trial to test the effectiveness
and cost-effectiveness of the programme and provide in-
formation necessary to design the trial.
Design
A feasibility trial using a parallel group randomised con-
trolled trial design will be carried out in six sites in the
southwest of England. Participants will be randomly allo-
cated to receive the group-based programme and access
to online programme resources or to a control group re-
ceiving access to the online resources only. Data collec-
tion will take place at three time points in both trial
arms at baseline (prior to randomisation), immediately
post-intervention, and 6 months later. As the interven-
tion can be delivered over 6 or 12 weeks, the post-
intervention data collection time point will vary relative
to randomisation but will be consistent in terms of the
amount of time passing after completion of the interven-
tion. Participants in the control arm in each randomised
site will complete measures at the same time as partici-
pants in the intervention arm for that site. The two arms
will therefore be balanced in terms of the timing of out-
come measures. The trial design and the flow of partici-
pants through the trial are illustrated in the trial flow
chart and SPIRIT figure (Fig. 1 and Table 1). The
SPIRIT checklist is provided as an additional file (see
Additional file 1).
Public involvement
This project has a strong ethos of parent carer and
stakeholder engagement from inception. The public in-
volvement in this project will ensure the following: (a)
the research is conducted in an acceptable manner, (b)
the research outputs are relevant and useful to parents
of children with special educational needs and disabil-
ities, and (c) our dissemination materials and methods
are appropriate and accessible.
Over 40 parents of children with a range of conditions
from the PenCRU Family Faculty public involvement
group have participated in a study-specific working
group since 2014. Our Stakeholder Advisory Group
(SAG) includes representatives from the local authority,
public health, parent carer forums, relevant charities,
and special schools.
Parent carers have been involved in all stages of devel-
oping the intervention and designing the feasibility trial
including:
a) Proposing the idea for the project based on their
needs and experiences
b) Co-designing and refining the intervention and
training content and delivery methods
c) Providing feedback on research methods including
the selection of the comparison conditions
d) Advising on the content and form of the Resource
Use Questionnaire for use as part of the cost-
effectiveness framework
e) Contributing to interpreting and disseminating the
findings of the previous study
f) Interviewing and hiring research staff
g) Discussing and advising on the design of the
feasibility trial
h) Recommending responses to peer reviews when
applying for funding.
Study setting and location
In collaboration with our SAG, we will identify six
venues (e.g. schools, community centres, adult and com-
munity learning venues) where it is possible to establish
and host a group. We will agree days, times, durations
Bjornstad et al. Pilot and Feasibility Studies           (2019) 5:137 Page 3 of 13
and frequencies of sessions, and local named organisers
for each venue.
Sample size
We aim to recruit 96 participants, to be allocated on 1:1
ratio to intervention and control. This is a large enough
sample to estimate the percentage providing data at
follow-up (assumed to be 80%—76 participants) with a
margin of error of 10 percentage points based on the
lower bound of the 95% confidence interval. Assuming
that 38 participants are followed up in each trial arm,
this will be large enough to estimate the standard devi-
ation for continuous outcomes in each arm within 29%
of its true value based on the upper bound of the 95%
confidence interval. Finally, 76 participants at follow-up
are large enough to estimate a correlation coefficient of
0.5 between baseline and follow-up scores for a continu-
ous outcome with a margin of error of 0.19 based on the
lower bound of the 95% confidence interval. We will
randomise a minimum of 8 and a maximum of 24
participants at each of the 6 sites. This will mean that
4–12 participants will be allocated to each of the inter-
vention and control trial arms at each site. We expect
the ideal group size to be between 6 and 12 people but
are allowing for potential attrition and variation in re-
cruitment between sites.
Inclusion criteria
People meeting the inclusion criteria are (1) primary
carers of children with additional needs and/or disabil-
ities (participants who self-identify as primary carers are
eligible; the child can be up to 25 years old consistent
with the current Department of Health and Department
of Education Special Educational Needs and Disability
(SEND) legislation in England and The Children’s Act;
no named diagnosis is necessary, and we are not limiting
to specific conditions), (2) willing and able to attend the
programme group meeting session(s) on arranged dates/
times, and (3) able to access online information.
Fig. 1 Trial flow chart
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Table 1 Schedule of enrolment, interventions, and assessments
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Exclusion criterion
Potential participants who are not able to communicate
in English are excluded. This is necessary because the
programme has not yet been translated into other
languages.
Recruitment
We will advertise the study in several ways. Press re-
leases and interviews in local television and/or radio will
be used to publicise the study. Members of our SAG will
be asked to advertise the project to their members
through their email lists and networks. We will also
share study adverts and information via social media and
through the PenCRU Family Faculty email list, asking
the members to share in their networks. We will liaise
with Information and Advice Services in each locality,
staff in social services, and Special Educational Needs
Coordinator (SENCOs) in schools in each study site to
target potentially more isolated parent carers. We will
also recruit participants at events for parent carers at the
study venues and other venues in the southwest where
interested parent carers can discuss the project with the
research team. This recruitment strategy uses many dif-
ferent approaches because parent carers do not all access
the same services and not all parent carers are con-
nected with their local parent carer forums. We will ask
all participants how they heard about the study during
screening, and this information will be recorded to as-
sess whether some recruitment methods may be more
effective than others. However, we are mindful that
while some methods may not result in large numbers of
recruits, they may help us to reach parent carers who
are more isolated and more in need of support and, as
such, will be seen as important methods to take forward
in a definitive trial.
Interested parent carers will contact the researchers.
There will be a telephone or face-to-face screening to
check the eligibility, understanding of the study, and to
answer any questions. A researcher will meet each po-
tential participant individually. Those who want to par-
ticipate will sign a consent form and complete baseline
questionnaires online using an electronic patient-
reported outcome (ePRO) system with a researcher on
hand for support as necessary [30]. Reasons for not con-
senting to participate will be recorded if provided by
those who decline.
Allocation to trial arms
When recruitment is completed at each site, we will
proceed to randomisation. Each of the six programme
groups will constitute a study site, with participants who
choose that group being randomised to either attend the
group or receive the online resources only. A computer-
generated randomisation sequence will be used to assign
the participants in each site to the intervention and con-
trol arms. A block randomisation scheme will be imple-
mented to ensure balance in the number of participants
allocated to each trial arm, stratified by group delivery
site. The allocation sequence will be concealed from re-
searchers using an online central randomisation service
setup and maintained by the Exeter Clinical Trials Unit
(UKCRC Registration ID 65). Blinding will not be used
in this trial.
All participants will receive an email and letter indicat-
ing the result of randomisation. The participants ran-
domly allocated to the intervention arm will be sent
details of the group sessions and be contacted by their
lead facilitator before the first group session. Participants
in both arms will receive a link to the online programme
resources and instructions on the web page. We will
monitor the number of participants who refuse partici-
pation and record their reasoning (if they wish to share
it) to gauge the acceptability of our trial design.
Intervention
The group-based programme was developed using Inter-
vention Mapping approach [28]. Full details of the inter-
vention, including its development, logic model, and
content (e.g. activities, behaviour change techniques), are
available in a previous publication [29]. In brief, the
programme aims to expand parent carers’ social net-
works and provide social support from peers with a
shared sense of social identity alongside targeted activ-
ities to improve parent carers’ confidence, motivation,
self-efficacy, and empowerment, thus creating the condi-
tions for change necessary for them to feel able to make
their own plan to prioritise healthy behaviours for
themselves.
The programme content is based around a set of uni-
versal and evidence-based actions (called CLANGERS)
associated with health and well-being. CLANGERS
stands for Connect, Learn, be Active, Notice, Give, Eat
well, Relax and Sleep [31]. The ‘CLANG’ component
comprises the ‘Five Ways to Wellbeing’ based on the evi-
dence from the foresight project on Mental Capital and
Wellbeing [32]. Each of these behaviours is potentially
more difficult for parent carers.
The programme content is organised into 12 modules
lasting 2 h each. The modules can be delivered weekly
over 6 sessions (comprising 2 modules per session) or 12
sessions (1 module per session). Our Family Faculty PPI
working group suggested that offering either 6 longer
sessions in the daytime or 12 shorter evening sessions
would be reasonable for most parent carers. One or both
options will be offered per area in order to maximise re-
cruitment and to reflect likely real-world delivery in
community settings, with 6 groups being delivered in
the study in total. If uptake is very low for a particular
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site, the delivery model may be adapted during recruit-
ment to increase numbers.
Facilitators
The lead facilitators of the group-based programme will
be experienced facilitators of the ‘Expert Parent
Programme’ courses created by the Council for Disabled
Children (CDC) with funding from the Department of
Health. The facilitators are parent carers. CDC has a selec-
tion process, trains, and provides supervision for their
facilitators to ensure that they facilitate the groups effect-
ively. Their nationwide network of over 70 facilitators pro-
vides a sustainable model for the implementation of the
programme in the future. Facilitators will use the Healthy
Parent Carers Facilitator Manual that includes module
outlines, content, timings, activities, and resources needed.
The Facilitator Manual also includes safeguarding proce-
dures for the facilitator to follow in case of any adverse
events such as suicidal ideation or disclosure of safeguard-
ing issues.
There will also be an assistant facilitator in each group
to assist the facilitator in sessions. We will recruit a local
parent carer for this role using a person specification de-
tailing the required personal qualities and skills and a se-
lection process.
We will provide training for lead and assistant facilita-
tors. The training will take place over 4 days for lead
facilitators and 2 days for assistant facilitators; it will be
delivered by researchers and the parent carer co-
investigators who co-developed the programme and facili-
tated the group in our previous study. Lead facilitators will
receive ongoing supervision and support through the
CDC and support from the research team. Conference
calls with facilitators, assistants, and researchers will be
convened to reflect on delivery of the sessions. These dis-
cussions will inform intervention design and training
needs and provide a forum to share ideas and ways to ad-
dress any challenges arising.
The Healthy Parent Carers online resources are part of
the intervention. They reflect the content of the group
sessions, provide space to write down reflections, and
prompts to set specific goals and for self-monitoring of
CLANGERS-related behaviours.
If the participants in the group programme miss a ses-
sion, they will be telephoned by the facilitator, who will
summarise the session and encourage the participant to
reflect on their week, read the section of the HPC online
resources, and set their weekly goals.
Control
Participants in the control arm will receive access to the
HPC programme resources online with instructions.
Risk of contamination between participants allocated to
each arm is low because the intervention is predicated
on participants developing a shared social identity as
members of the HPC group. Participants in both arms
will be asked whether they have had contact with partici-
pants in the other arm of the trial as part of a post-
intervention feedback form.
Data collection
Study records
We will record the data on the feasibility of recruitment,
including how many people respond to the adverts, how
they heard about the study, reasons for not taking part
for those who decline, and how many are successfully re-
cruited. We will record delivery setting, delivery model,
attendance, attrition, and reasons for missed sessions or
withdrawal from the study. We will also monitor how
long it takes to accrue the target number of participants
at each site and at what point in the trial process any
participants withdraw.
Sample characteristics
Demographic data will include gender, ethnicity, parent re-
lationship status, number of children, employment status,
level of education, income, housing status, and age, gender,
and diagnosis (if any) of their disabled child. We will also
collect information about their disabled child’s functioning
and health complexity using the About my Child measure
(AMC-19) [33]. We will also use participants’ postcodes to
link with the Indices of Multiple Deprivation as an indicator
of deprivation relative to England and Wales in the area
where participants live [34].
Outcome measures
Participants will be asked to complete all measures be-
fore randomisation, immediately post-intervention, and
6 months post-intervention, regardless of attendance or
engagement with the interventions. Based on the recom-
mendations from our Family Faculty PPI working group,
the measures will be available to complete online, using
a computer, smartphone, or tablets. The Exeter Clinical
Trials Unit will set up an online platform for partici-
pants to access and complete the measures. Participants
may request to complete the measures on paper if they
wish. Any measures completed on paper will be inde-
pendently double-entered by two researchers. These
requests will be monitored to track preferences for on-
line- versus paper-based measures.
Two members of our Family Faculty PPI working
group have tested the applicability and time to complete
the measures (45 min). A £25 shopping voucher will be
posted to participants as acknowledgement for complet-
ing measures at each time point.
The measures will comprise:
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a) Warwick-Edinburgh Mental Well-being Scale
(WEMWBS): The WEMWBS is a 14-item scale
used to assess the mental well-being in the general
population and in the evaluation of programmes
aiming to improve mental well-being [35].
Responses are normally distributed in the general
population. WEMWBS has been validated in the
UK, Europe, and elsewhere. It has been tested with
minority ethnic populations, users of mental health
services, and carers. It is sensitive to changes
occurring through participation in programmes that
promote well-being such as health promotion
programmes. A tariff of well-being-adjusted life-
year weights is currently being developed for
responses on the WEMWBS, which will enable the
measure to be used in cost-effectiveness analyses
recognised by the National Institute for Health and
Care Excellence (NICE) [36].
b) Patient Health Questionnaire-9 (PHQ-9): The
PHQ-9 is a 9-item measure that rates the frequency
of symptoms and is designed for screening,
diagnosing, monitoring, and measuring the severity
of depression [37–39]. Categories based on the
cutoff scores of 5, 10, 15, and 20 represent none,
mild, moderate, moderately severe, and severe de-
pression, respectively. As part of a safeguarding
protocol, we will use the Patient Health
Questionnaire (PHQ-9) to measure depressive
symptoms. The PHQ-9 questionnaire is
recommended by NICE to assess depression in
adults [40], and its use is highlighted in clinical
pathways [41], so the interpretation of scores is
widely understood by GPs and primary care staff.
There is good evidence, across a range of studies,
for the validity, reliability, sensitivity, and specificity
of the PHQ-9 for detecting depressive disorders [38,
39]. It can be administered repeatedly to assess
change in depression in response to treatment.
Question 9 screens for suicidal ideation. If the
person scores higher than 0 on question 9, or at
any other point discloses suicidal ideation, we will
follow the safeguarding protocol.
c) EuroQol 5 Dimensions (EQ-5D-5 L): The EQ-5D-5
L is a measure of health-related quality of life. It
consists of five items measuring five dimensions of
health-related quality of life (mobility, self-care,
usual activities, pain/discomfort, and anxiety/de-
pression) and a vertical visual analogue scale
measuring self-rated health [42]. QALY weights can
be applied to EQ-5D scores, which can then be
used to calculate QALYs, and the cost-per-QALY
of the intervention in a future definitive trial. The
EQ-5D is NICE’s preferred measure for use in
health technology cost-effectiveness analyses.
d) Parents’ Assessment of Protective Factors (PAPF):
The PAPF is a 36-item measure that assesses
protective factors identified in the development of
the Strengthening Families evidence-based
parenting programme [43]. These protective factors
are as follows: parental resilience, social
connections, concrete support in times of need, and
support of children’s social and emotional
competence. These factors relate to the
determinants of change in the logic model for the
Healthy Parent Carers Programme.
e) Health Promoting Activities Scale (HPAS): The
HPAS is an 8-item measure of a person’s estimation
of the frequency with which they participate in a
range of activities that promote or maintain health
and well-being [44, 45]. It was developed for and
validated with mothers of children with disabilities.
f) Patient Activation Measure (PAM): The PAM is a
13-item measure that measures the spectrum of
skills, knowledge, and confidence in patients and
captures the extent to which people feel engaged
and confident in managing their own health and
care [46, 47]. It has been tested with 100,000
patients with long-term conditions in England to
establish the feasibility of using the PAM across the
NHS, how activation can inform support for self-
management, what support clinicians and
commissioners need to use the measure effectively,
and whether supporting activation can improve
outcomes for patients in the NHS.
g) ICEpop CAPability measure for Adults (ICECAP-
A): The ICECAP-A is a 5-item measure of
capability, which includes the following aspects of
well-being found to be important to adults in the
UK: attachment, stability, achievement, enjoyment,
and autonomy [48–50]. A set of UK well-being
adjusted life-year weights are available for the
ICECAP-A, enabling it to be used in economic
evaluations.
h) Resource use questionnaire: We developed a study-
specific resource use questionnaire in collaboration
with parent carers. This includes health, social care,
participant, and broader societal resource use, and
draws on measures in the Database of Instruments
for Resource Use Measurement (DIRUM) [51].
Process evaluation
In line with the MRC guidance on process evaluations,
this study will include a process evaluation that is appro-
priate for the feasibility testing stage of the development-
evaluation-implementation process for this intervention
[52]. This process evaluation will allow for the exploration
of the feasibility of implementation of the intervention by
assessing uptake (recruitment) and retention, participant
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engagement, fidelity of delivery (to content and quality),
experiences of participants and facilitators, unintended
consequences, and contextual factors which may influence
experience and delivery.
The following data collection tools will be used to
assess fidelity of intervention delivery, participant
and trainer characteristics/motivations, trainer know-
ledge and self-efficacy to deliver the programme,
participant engagement with the programme/online
materials, and acceptability of the intervention and
trial design.
a) Facilitator pre-training questionnaire: We will use a
pre-training questionnaire to collect information
about facilitators’ characteristics, their motivations
to take part, relevant background and experience,
and expectations of delivering the programme.
b) Facilitator training feedback: Following delivery of
the training, we will use a questionnaire to gather
the facilitators’ feedback about their self-reported
knowledge, understanding, skills, and confidence to
deliver the intervention and to gather their reflec-
tions on the training.
c) Facilitator delivery observations: We will use a
checklist to assess lead facilitators’ competence to
deliver while observing their delivery of the
programme content during the facilitator training.
The checklist includes key skills and competencies
linking to the objectives of the lead facilitator
training and will enable trainers and research staff
to assess facilitators’ readiness to deliver the
programme. This will also help to guide and plan
additional or future training.
d) Facilitator checklist, records, and support calls: We
will use a self-report checklist completed jointly by
the facilitators to indicate which content they have
covered in each session (adherence), the duration of
the sessions (dose), and the participants’ engage-
ment. Facilitators will be asked to record attendance
at each session. We will also arrange support calls
with facilitators to gather more information about
how the groups are going and any challenges to
delivery.
e) Session recordings: We will audio-record group
sessions and will sample two to three recordings
from each group to assess fidelity to intervention
content, quality of delivery, and participant engage-
ment. A researcher will rate the delivery using the
same checklist used by the facilitators after each
session. A second researcher will rate one recording
per group (n = 6, 14%). The two researchers will
compare the scoring of the first three groups
immediately, and any inconsistencies will be
discussed with JL/MT, to ensure there is a clear
understanding of the assessment criteria. The scores
of the double-coded sessions will be agreed between
researchers, and the sessions assessed by the
researchers will be compared with the facilitators’
scores.
f) Participants’ feedback: We will collect feedback
from treatment and control arm participants
about the programme content and delivery, their
experiences, and whether they had contact with
participants in the other arm of the trial via
feedback forms at the end of each group session
for those in the intervention arm and at the end
of the programme for those in both trial arms.
g) Participant interviews: We will sample
purposively 12 participants (from different
groups) in the intervention arm and 6
participants allocated to the control arm across
all sites for semi-structured telephone interviews.
For the intervention arm, these interviews will
explore participants’ experiences of, and engage-
ment in, the programme and the group and their
views on the group content, activities, and facili-
tators. All, control and intervention groups, par-
ticipants will be asked in the interviews about
engagement with online resources, perceived im-
pact of the programme and any potential con-
textual influences, and acceptability of the trial
processes and measures. We will also sample up
to 4 participants (from different groups) who
were allocated to the intervention arm of the
trial but did not attend any group sessions to
ask them about barriers to attending and
whether anything could be done to promote at-
tendance in future groups. All interviews with
participants will last approximately 30 min and
will be audio-recorded and transcribed verbatim,
with names and other personal identifying
information changed to protect confidentiality.
Interviews will take place as soon as possible
after the participants have completed their post-
intervention measures and before they complete
their 6-month follow-up measures.
h) Focus groups with facilitators: We will invite all
lead facilitators and assistant facilitators to a
focus group after the end of all groups. The
focus group (lasting approximately 2 h) will cover
facilitators’ experiences of delivering, and
engagement with, the programme, views on the
programme content, activities and feasibility of
programme delivery, facilitator training and skills,
group management, and suggestions for
improvements. The focus group will be audio-
recorded and transcribed verbatim (with any po-
tentially identifiable information anonymised).
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Cost-effectiveness framework
We will develop and test a framework for assessing the
cost-effectiveness of the intervention in a future rando-
mised trial. We will:
a) Establish methods for estimating intervention
resource use and costs (e.g. training of facilitators,
facilitators’ time, venue hire), in collaboration with
the programme facilitators and site representatives
b) Develop a resource use questionnaire in collaboration
with parent carers, drawing on measures in the
Database of Instruments for Resource Use
Measurement (DIRUM) repository [51]
c) Assess the acceptability to parent carers of the EQ-
5D-5 L, the ICECAP-A, and the WEMWBS, judged
by missing data and measurement properties [53].
Data analysis
Statistical/quantitative analysis
We will report the number of eligible people who self-
refer and the percentage (with 95% confidence intervals
(CIs)) of these that are randomised in the trial. These
findings will also be reported separately for each type of
delivery setting and delivery model to assess whether
particular delivery settings or models are more popular
and therefore would lead to higher recruitment rates in
the subsequent definitive trial. We will also report num-
bers and percentages of people who heard about the
study via different sources, organised into categories.
We will also report the percentage (with 95% confi-
dence intervals) of participants who complete each as-
sessment at each time point as an assessment of the
acceptability of the measures and of the feasibility of col-
lecting sufficient data in a definitive trial. We will sum-
marise the characteristics of recruited participants using
demographic data to allow for assessment of the repre-
sentativeness of the sample relative to figures available
from the Office for National Statistics on the population
in the southwest of England. We will also report the
baseline comparability of the trial arms with respect to
demographics and outcome measures.
For the intervention arm, we will report the number
and percentage of participants that attend each group
session with 95% confidence intervals. The percentage of
participants that are lost to follow-up at each follow-up
point will be reported for each trial arm. Select charac-
teristics (parent carer gender and age, child gender and
age, Index of Multiple Deprivation quintile, study site
(centre), and baseline scores on outcomes) will be com-
pared between those who are and are not lost to follow-
up within each trial arm using descriptive summaries,
but no formal statistical tests. Acceptability, judged by
missing data of EQ-5D-5 L and ICECAP-A, will help to
plan methods for estimation of cost-effectiveness in the
future trial.
Means, standard deviations, and the correlation be-
tween baseline and follow-up scores on continuous out-
comes will be reported to inform the sample size
calculation for the subsequent definitive trial.
Level of clustering within groups in the intervention
arm will be quantified using the intra-cluster (intra-
group) correlation coefficient to inform the sample size
calculation for the definitive trial; however, we recognise
the relatively small sample size for this purpose, and it
will be used alongside information about levels of clus-
tering in published studies of trials of similar group-
based interventions in similar settings.
We will compare the outcomes at follow-up between
the two trial arms based on the intention-to-treat
principle with participants analysed according to the trial
arm they were randomised to. Missing data will not be
imputed. We will report only confidence intervals for
the intervention effect and no p values, in line with the
extension to the CONSORT statement for reporting
randomised pilot and feasibility studies [54].
Analysis of process data
Descriptive statistics will be reported for the quantitative
data collected in delivery observation checklists, facilita-
tor checklists, checklists used to assess intervention ses-
sion recordings, and participant feedback forms.
Qualitative data collected from feedback forms, inter-
views, and focus groups will be analysed thematically to
provide insights into participants’ experiences of the
programme, intervention acceptability, and suggestions
for improvement, and to enhance understanding of the
impact of the intervention and the mechanisms of
change in relation to the programme logic model [54].
Data will be analysed using inductive thematic analysis
[55] separately for each data source (i.e. feedback com-
ments, interviews, and focus groups), following the same
approach. Some issues will emerge as more salient than
others and the interpretation of findings will be influ-
enced by the original research objectives as well as the
themes emerging directly from the data.
NVivo software (version 12 Pro for Windows, QSR
International) will be used to organise and analyse the
qualitative data. Initially, two researchers will independ-
ently read and code line-by-line a sample of the data and
discuss their coding to develop and agree on the coding
framework. New codes may be added as the coding pro-
ceeds, and the codes and coded data will be reviewed.
Codes will be defined, compared to each other, and
organised into categories and themes. Attention will be
paid to negative, or ‘deviant’, cases to inform developing
themes and interpretation. Short summaries of each
interview will be also written to explore how individual
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experiences and views of the intervention may differ be-
tween participants. The analysis and interpretation of
the data will be regularly discussed with the research
team. A detailed record will be kept of the analysis
process, including definitions of the themes and con-
cepts and their application.
Discussion
We will interpret the findings of this feasibility trial and
report the implications for progression to a definitive
randomised controlled trial of the HPC programme.
This will include any necessary amendments to the
intervention content and delivery, as well as the develop-
ment of a train-the-trainer manual to be used in training
future facilitators of the programme. The following indi-
cators of feasibility will be used to determine whether a
definitive randomised controlled trial is feasible with the
current trial design and procedures:
a) Recruit a minimum of 48 participants, which is the
minimum number that will enable all six sites to be
randomised and the intervention to be tested
b) Deliver 6 groups in total for the intervention arm,
assessed by establishing 6 venues, and identifying
and training facilitators, and groups completing the
programme curriculum
c) At least 80% of participants completing measures at
6-month follow-up or a clear plan to achieve this in
the trial
If any of these indicators are not met, the research
team will consider whether a definitive trial may not be
feasible or whether changes to the design or procedures
and further feasibility testing are needed. The need to
translate programme materials into other languages will
also be taken into account for a subsequent trial.
A complete and transparent report of the trial will be
produced with reference to recommendations of the
CONSORT 2010 statement: extension to randomised
pilot and feasibility trials, including a CONSORT partici-
pant flow chart [54]. The report will be written for pub-
lication in a peer-reviewed, open access, academic
journal with authorship eligibility determined by follow-
ing the International Committee of Medical Journal Edi-
tors recommendations [56]. A plain language summary
of the findings will also be co-produced with members
of our Family Faculty public involvement group and sent
to trial participants and organisations that help to recruit
participants and host the groups. We will consult our
Family Faculty and Stakeholder Advisory Group for ad-
vice on ways to disseminate the findings.
NHS England’s Commitment to Carers states ‘Helping
carers to provide better care and to stay well themselves
will contribute to better lives for those needing care and
more effective use of NHS resources’ [57]. However,
there is currently a paucity of interventions that promote
health for parent carers. This feasibility trial and a subse-
quent definitive trial may have important implications
for a public health strategy for parent carers of children
with disabilities in the UK. It will also inform research
and public health policy internationally, as the higher
risk of psychological and physical health problems in
parent carers is not limited to the UK.
Project timetable and milestones
The main milestones are as follows. Ethical approval for
the study was received on 20 August 2018. The trial was
registered on 25 October 2018 (ISRCTN 15144652). Re-
cruitment of participants began on 29 October 2018.
The analysis of data on fidelity and process evaluation
will be conducted following data collection (summer to
autumn 2019). The analyses of outcome measures will
be conducted in February 2020. The expected date of
completion is June 2020.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s40814-019-0517-3.
Additional file 1. SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents*.
Abbreviations
AMC-19: About my Child measure; CDC: Council for Disabled Children;
CLANGERS: Connect, Learn, be Active, Notice, Give, Eat well, Relax, and Sleep;
CONSORT: Consolidated Standards of Reporting Trials; DIRUM: Database of
Instruments for Resource Use Management; EQ-5D-5 L: EuroQol 5
Dimensions; HPAS: Health Promoting Activities Scale; HPC: Healthy Parent
Carers; ICECAP-A: ICEpop CAPability measure for Adults; NIHR: National
Institute for Health Research; PAM: Patient Activation Measure; PAPF: Parents’
Assessment of Protective Factors; PenCLAHRC: The National Institute for
Health Research (NIHR) Collaboration for Leadership in Applied Health
Research and Care (CLAHRC) South West Peninsula; PenCRU: Peninsula
Cerebra Research Unit; PHQ-9: Patient Health Questionnaire-9; PPI: Patient
and public involvement; SAG: Stakeholder Advisory Group; SEND: Special
educational needs and disability; WEMWBS: Warwick-Edinburgh Mental Well-
being Scale
Acknowledgements
We thank members of the PenCRU Family Faculty and the Stakeholders
Advisory Group for their involvement in the development of the intervention
and the design of this study.
Study Sponsor
University of Exeter, Research Ethics and Governance Office, University of
Exeter, Lafrowda House, St Germans Road, Exeter, Devon, EX4 6TL
Authors’ contributions
All authors contributed. CM led the development and preliminary evaluation
of the programme and leads the study and public involvement work. GB
and CM drafted the initial study design. AB, AM, MF, and CM designed the
original programme. OU designed the quantitative analysis plan. AH
designed the methods to develop and test a cost-effectiveness framework.
AB, CM, VB, JL, MT, KW, and BCF designed the fidelity and process evaluation.
KF facilitated public involvement. SR coordinated the CTU involvement in
the design and conduct of the project. SL facilitated infrastructure support
through National Institute for Health Research Applied Research
Bjornstad et al. Pilot and Feasibility Studies           (2019) 5:137 Page 11 of 13
Collaboration South West Peninsula. All authors contributed to drafting and
refining the study protocol and approved the final manuscript. The study
Sponsor is the University of Exeter.
Funding
This paper presents independent research funded by the National Institute
for Health Research (NIHR) under its Research for Patient Benefit (RfPB)
Programme (Grant Reference Number PB-PG-0317-20044). We also acknow-
ledge support from the National Institute for Health Research Applied Re-
search Collaboration South West Peninsula. The views and opinions
expressed in this paper are those of the authors and not necessarily those of
the National Institute for Health Research or the Department of Health and
Social Care. Delivery of the Healthy Parent Carers programme is funded by
Public Health England, Kernow Clinical Commissioning Group, Northern, East-
ern and Western Devon Clinical Commissioning Group, and a grant from the
National Lottery Community Fund through the Reaching Communities
programme. Peer review of the study design was provided during the NIHR
funding application process. The funders have had no involvement in the
writing of the manuscript and will not have any role during its execution,
analyses, interpretation of the data, writing of the report, or the decision to
submit the report for publication.
Availability of data and materials
Not applicable
Ethics approval and consent to participate
Ethics approval for the study was received on 20 August 2018 from the
University of Exeter Medical School Research Ethics Committee in the
College of Medicine and Health (UEMS REC 18/06/174); recruitment is
currently ongoing.
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Author details
1Peninsula Childhood Disability Research Unit (PenCRU) and National
Institute for Health Research Applied Research Collaboration South West
Peninsula (PenARC), University of Exeter Medical School, University of Exeter,
St. Luke’s Campus, Heavitree Road, Exeter EX1 2LU, UK. 2Nuffield Department
of Primary Care Health Sciences, Medical Sciences Division, Radcliffe
Observatory Quarter, University of Oxford, Woodstock Road, Oxford OX2
6GG, UK. 3National Institute for Health Research Applied Research
Collaboration South West Peninsula (PenARC), University of Exeter Medical
School, University of Exeter, St. Luke’s Campus, Heavitree Road, Exeter EX1
2LU, UK. 4Health Economics Group, University of Exeter Medical School,
University of Exeter, St. Luke’s Campus, Heavitree Road, Exeter EX1 2LU, UK.
5PenCRU Family Faculty, University of Exeter Medical School, University of
Exeter, St. Luke’s Campus, Heavitree Road, Exeter EX1 2LU, UK. 6Exeter Clinical
Trials Unit, University of Exeter Medical School, University of Exeter, St. Luke’s
Campus, Heavitree Road, Exeter EX1 2LU, UK.
Received: 2 April 2019 Accepted: 15 October 2019
References
1. Blackburn CM, Spencer NJ, Read JM. Prevalence of childhood disability and
the characteristics and circumstances of disabled children in the UK:
secondary analysis of the Family Resources Survey. BMC Pediatr. 2010;10(21):
1471–2431.
2. Barlow J, Cullen-Powell L, Cheshire A. Psychological well-being among
mothers of children with cerebral palsy. Early Child Dev Care.
2006;176(3–4):421–8.
3. Brehaut JC, Kohen DE, Raina P, Walter SD, Russell DJ, Swinton M, O’Donnell
M, Rosenbaum P. The health of primary caregivers of children with cerebral
palsy: how does it compare with that of other Canadian caregivers?
Pediatrics. 2004;114(2):e182–91.
4. Brehaut JC, Kohen DE, Garner RE, Miller AR, Lach LM, Klassen AF,
Rosenbaum PL. Health among caregivers of children with health problems:
findings from a Canadian population-based study. Am J Public Health. 2009;
99(7):1254–62.
5. Emerson E. Mothers of children and adolescents with intellectual disability:
social and economic situation, mental health status, and the self-assessed
social and psychological impact of the child’s difficulties. J Intellect Disabil
Res. 2003;47(4–5):385–99.
6. Gallagher S, Phillips AC, Oliver C, Carroll D. Predictors of psychological
morbidity in parents of children with intellectual disabilities. J Pediatr
Psychol. 2008;33(10):1129–36.
7. Lach LM, Kohen DE, Garner RE, Brehaut JC, Miller AR, Klassen AF,
Rosenbaum PL. The health and psychosocial functioning of caregivers of
children with neurodevelopmental disorders. Disabil Rehabil.
2009;31(9):741–52.
8. Murphy NA, Christian B, Caplin DA, Young PC. The health of caregivers for
children with disabilities: caregiver perspectives. Child Care Health Dev.
2007;33(2):180–7.
9. Oelofsen N, Richardson P. Sense of coherence and parenting stress in
mothers and fathers of preschool children with developmental disability. J
Intellect Dev Disabil. 2006;31(1):1–12.
10. Olsson MB, Hwang C. Depression in mothers and fathers of children with
intellectual disability. J Intellect Disabil Res. 2001;45(6):535–43.
11. Singer GH, Floyd F. Meta-analysis of comparative studies of depression in
mothers of children with and without developmental disabilities. Am J
Ment Retard. 2006;111(3):155–69.
12. Tong HC, Haig AJ, Nelson VS, Yamakawa KS-J, Kandala G, Shin KY. Low back
pain in adult female caregivers of children with physical disabilities. Arch
Pediatr Adolesc Med. 2003;157(11):1128–33.
13. Lee M, Park C, Matthews AK, Hsieh K. Differences in physical health, and
health behaviors between family caregivers of children with and without
disabilities. Disabil Health J. 2017;10:565–70.
14. Arim RG, Miller AR, Kohen DE, Guèvremont A, Lach LM, Brehaut JC. Changes
in the health of mothers of children with neurodevelopmental disabilities:
an administrative data study. Res Dev Disabil. 2019;86:76–86.
15. Brehaut JC, Garner RE, Miller AR, Lach LM, Klassen AF, Rosenbaum PL, Kohen
DE. Changes over time in the health of caregivers of children with health
problems: growth-curve findings from a 10-year Canadian population-based
study. Am J Public Health. 2011;101(12):2308–16.
16. Resch JA, Mireles G, Benz MR, Grenwelge C, Peterson R, Zhang D. Giving
parents a voice: a qualitative study of the challenges experienced by
parents of children with disabilities. Rehabil Psychol. 2010;55(2):139–50.
17. Council for Disabled Children. Expert Parent Programme. https://
councilfordisabledchildren.org.uk/our-work/whole-child/practice/expert-
parent-programme. Accessed 21 Jan 2019.
18. Singer GH, Ethridge BL, Aldana SI. Primary and secondary effects of parenting
and stress management interventions for parents of children with
developmental disabilities: a meta-analysis. Dev Disabil Res Rev. 2007;13(4):357–
69.
19. Dykens EM, Fisher MH, Taylor JL, Lambert W, Miodrag N. Reducing distress
in mothers of children with autism and other disabilities: a randomized trial.
Pediatrics. 2014;134(2):e454–63.
20. Shilling V, Morris C, Thompson-Coon J, Ukoumunne O, Rogers M, Logan S.
Peer support for parents of children with chronic disabling conditions: a
systematic review of quantitative and qualitative studies. Dev Med Child
Neurol. 2013;55(7):602–9.
21. Law E, Fisher E, Eccleston C, Palermo TM. Psychological interventions for
parents of children and adolescents with chronic illness. Cochrane Database
of Systematic Reviews 2019, Issue 3. Art. No.: CD009660. https://doi.org/10.
1002/14651858.CD009660.pub4.
22. Cachia RL, Anderson A, Moore DW. Mindfulness, stress and well-being in
parents of children with autism spectrum disorder: a systematic review. J
Child Fam Stud. 2016;25(1):1–14.
23. Jetten J, Haslam C, Alexander SH. The social cure: identity, health and well-
being: Psychology press; 2012.
24. Borek A, Abraham C, Greaves C, Gillison F, Tarrant M, Morgan-Trimmer S,
McCabe R, Smith J: Identifying change processes in group-based health
behaviour-change interventions: Development of the Mechanisms of Action
in Group-based Interventions (MAGI) framework. Health Psychol Rev. 2019:
1–21. https://doi.org/10.1080/17437199.2019.1625282.
25. Tarrant M, Khan SS, Farrow CV, Shah P, Daly M, Kos K. Patient experiences of
a bariatric group programme for managing obesity: a qualitative interview
study. Br J Health Psychol. 2017;22(1):77–93.
Bjornstad et al. Pilot and Feasibility Studies           (2019) 5:137 Page 12 of 13
26. Haslam C, Cruwys T, Haslam SA, Dingle G, Chang MX-L. Groups 4 Health:
evidence that a social-identity intervention that builds and strengthens social
group membership improves mental health. J Affect Disord. 2016;194:188–95.
27. Peninsula Childhood Disability Research Unit. Our Family Faculty. http://
www.pencru.org/getinvolved/ourfamilyfaculty/. Accessed 29 Jan 2019.
28. Bartholomew LK, Parcel GS, Kok G, Gottlieb NH, Fernandez ME. Planning
health promotion programs: an intervention mapping approach. 4th ed.
San Francisco: Jossey-Bass; 2016.
29. Borek AJ, McDonald B, Fredlund M, Bjornstad G, Logan S, Morris C. Healthy
Parent Carers programme: development and feasibility of a novel group-
based health-promotion intervention. BMC Public Health. 2018;18(1):270.
30. Muehlhausen W, Doll H, Quadri N, Fordham B, O’Donohoe P, Dogar N, Wild DJ.
Equivalence of electronic and paper administration of patient-reported
outcome measures: a systematic review and meta-analysis of studies
conducted between 2007 and 2013. Health Qual Life Outcomes. 2015;13(1):167.
31. Hammond P. Staying alive: how to get the best out of the NHS - advice
from a doctor. London: Quercus; 2015.
32. Aked J, Marks N, Cordon C, Thompson S. Five ways to wellbeing: a report
presented to the foresight project on communicating the evidence base for
improving people’s well-being. London: Nef; 2009.
33. Williams U, Rosenbaum P, Gorter JW, McCauley D, Gulko R. Psychometric
properties and parental reported utility of the 19-item ‘About My Child’
(AMC-19) measure. BMC Pediatr. 2018;18(1):174.
34. Department for Communities and Local Government. English indices of
deprivation 2015. https://www.gov.uk/government/statistics/english-indices-
of-deprivation-2015. Accessed 12 May 2017.
35. Tennant R, Hiller L, Fishwick R, Platt S, Joseph S, Weich S, Parkinson J, Secker
J, Stewart-Brown S. The Warwick-Edinburgh mental well-being scale
(WEMWBS): development and UK validation. Health Qual Life Outcomes.
2007;5(1):63.
36. National Institute for Health and Care Excellence. The social care guidance
manual. London: NICE; 2016.
37. Kroenke K, Spitzer RL. The PHQ-9: a new depression diagnostic and severity
measure. Psychiatr Ann. 2002;32(9):509–15.
38. Kroenke K, Spitzer RL, Williams JB, Löwe B. The patient health questionnaire
somatic, anxiety, and depressive symptom scales: a systematic review. Gen
Hosp Psychiatry. 2010;32(4):345–59.
39. Wittkampf KA, Naeije L, Schene AH, Huyser J, van Weert HC. Diagnostic
accuracy of the mood module of the Patient Health Questionnaire: a
systematic review. Gen Hosp Psychiatry. 2007;29(5):388–95.
40. National Collaborating Centre for Mental Health, Royal College of
Psychiatrists. Common mental health disorders: identification and pathways
to care: RCPsych Publications; 2011.
41. National Institute for Health and Care Excellence. Depression in adults:
recognition and management. https://www.nice.org.uk/guidance/cg90.
Accessed 21 Jan 2019.
42. The EuroQol Group. EuroQol-a new facility for the measurement of health-
related quality of life. Health Policy. 1990;16(3):199–208.
43. Kiplinger VL, Browne CH. Parents’ assessment of protective factors: user’s
guide and technical report. Washington: Center for the Study of Social
Policy; 2014.
44. Bourke-Taylor H, Law M, Howie L, Pallant JF. Initial development of the
Health Promoting Activities Scale to measure the leisure participation of
mothers of children with disabilities. Am J Occup Ther. 2012;66(1):e1–e10.
45. Muskett R, Bourke-Taylor H, Hewitt A. Intrarater reliability and other
psychometrics of the Health Promoting Activities Scale (HPAS). Am J Occup
Ther. 2017;71(4):7104190010p7104190011–8.
46. Hibbard JH, Mahoney ER, Stockard J, Tusler M. Development and testing of
a short form of the patient activation measure. Health Serv Res. 2005;
40(6p1):1918–30.
47. Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the Patient
Activation Measure (PAM): conceptualizing and measuring activation in
patients and consumers. Health Serv Res. 2004;39(4p1):1005–26.
48. Al-Janabi H, Flynn TN, Coast J. Development of a self-report measure of
capability wellbeing for adults: the ICECAP-A. Qual Life Res. 2012;21(1):167–76.
49. Al-Janabi H, Peters TJ, Brazier J, Bryan S, Flynn TN, Clemens S, Moody A,
Coast J. An investigation of the construct validity of the ICECAP-A capability
measure. Qual Life Res. 2013;22(7):1831–40.
50. Mitchell PM, Al-Janabi H, Byford S, Kuyken W, Richardson J, Iezzi A, Coast J.
Assessing the validity of the ICECAP-A capability measure for adults with
depression. BMC Psychiatry. 2017;17(1):46.
51. Ridyard CH, Hughes DA, Team D. Development of a database of
instruments for resource-use measurement: purpose, feasibility, and design.
Value Health. 2012;15(5):650–5.
52. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, Moore L,
O’Cathain A, Tinati T, Wight D. Process evaluation of complex interventions:
Medical Research Council guidance. BMJ. 2015;350:h1258.
53. Ridyard CH, Hughes DA. Taxonomy for methods of resource use
measurement. Health Econ. 2015;24(3):372–8.
54. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L,
Lancaster GA. CONSORT 2010 statement: extension to randomised pilot and
feasibility trials. Pilot Feasibility Stud. 2016;2(1):64.
55. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol.
2006;3(2):77–101.
56. International Committee of Medical Journal Editors. Defining the role of
authors and contributors. http://www.icmje.org/recommendations/browse/
roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html.
Accessed 18 Mar 2019.
57. NHS England: NHS England’s commitment to carers; 2014.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Bjornstad et al. Pilot and Feasibility Studies           (2019) 5:137 Page 13 of 13
